Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Advanced metastatic cancer poses utmost clinical challenges and may present molecular
and cellular features distinct from an early-stage cancer. Herein, we present single-cell …

Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …

Improving the efficacy of immune checkpoint therapies will require a better understanding of
how immune cells are recruited and sustained in tumors. Here, we used the …

Background Combining immune-checkpoint inhibitors with chemotherapy yielded an
increased response rates in patients with metastatic triple-negative breast cancer (TNBC) …

Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of
patients and can lead to a multitude of toxicities, suggesting the need for more targeted …